Probiotic Supplementations Preserve Protective Immunity Against SARS-CoV-2 Spike Protein After a Triple Combination of COVID-19 Vaccination
Keywords:Probiotics, SARS-CoV-2 spike protein IgG antibody level, COVID-19, Supplement
Introduction: Immunoglobulin G against SARS-CoV-2 spike protein declines over-time in vaccinated individuals. Trend to restore protective immunity is challenging.
Objectives: Probiotics have beneficial effects to human innate and adaptive immune responses. This study aimed to compare immune preservation of probiotic supplement versus placebo by measuring the mean and percent reduction of COVID-19 antibody level among those subjects receiving a triple dose combination of COVID-19 vaccine.
Methods: A randomized, double-blinded, placebo-controlled trial, conducted in Bangkok-Samui hospital between December 2021 to February 2022. There were 30 volunteers, divided randomly into 2 groups. The target group received probiotics supplement once daily for 6 weeks, while the control group received placebo. Blood testing for SARS-CoV-2 spike protein Immunoglobulin G level was collected at day baseline and week-6 visit. Data were analyzed by Statistical software with Statistical Package for the Social Sciences (SPSS) version 23.0, including descriptive and analytical statistics.
Results: The mean of SARS-CoV-2 spike protein IgG antibody level between probiotic and placebo group at the baseline was not difference (P = .4178). Subjects received probiotic supplement for 6 weeks found SARS-CoV-2 spike protein IgG antibody level reduction significantly (P = .003). The control group also found antibody level reduction significantly (P < .001). The Probiotic group found a significantly lower percent reduction of SARS-CoV-2 spike protein IgG antibody at week-6 visit from the baseline than the placebo group (35.7% vs. 48.3%, respectively, P = .007). There is no adverse event at the end of this study.
Conclusions: Taking probiotics supplement once daily for 6 weeks could preserve immunity level with less percent reduction than the placebo, with no adverse effect occurred.
Conte L, Toraldo DM. Targeting the gut–lung microbiota axis by means of a high-fibre diet and probiotics may have anti inflammatory
effects in COVID-19 infection. Ther Adv Respir Dis. 2020;14:1753466620937170.
Melenotte C, Silvin A, Goubet AG, et al. Immune responses during COVID-19 infection. Oncoimmunology. 2020;9(1):1807836.
Diao B, Wang C, Tan Y, et al. Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19). Front Immunol. 2020;11:827.
Zollner A, Watschinger C, Rossler A, et al. B and T Cell Response to SARS-CoV-2 Vaccination in Health Care Professionals With and Without Previous COVID-19. Rochester, NY: Social Science Research Network; 2021.
Zurac S, Nichita L, Mateescu B, et al. COVID-19 vaccination and IgG and IgA antibody dynamics in healthcare workers. Mol Med Rep. 2021;24(2):1-13.
Wisnewski AV, Campillo LJ, Redlich CA. Human IgG and IgA responses to COVID-19 mRNA vaccines. PloS One. 2021;16(6):e0249499.
Dhar D, Mohanty A. Gut microbiota and Covid-19- possible link and implications. Virus Res. 2020;285:198018.
Markowiak P, Slizewska K. Effects of Probiotics, Prebiotics, and Synbiotics on Human Health. Nutrients. 2017;9(9):1021.
Trompette A, Gollwitzer ES, Yadava K, et al. Gut microbiota metabolism of dietary fiber influences allergic airway disease and hematopoiesis. Nat Med. 2014;20(2):159-166.
Negi S, Das DK, Pahari S, Nadeem S, Agrewala JN. Potential Role of Gut Microbiota in Induction and Regulation of Innate Immune Memory. Front Immunol. 2019;10:2441.
Gutierrez-Castrellon P, Gandara-Marti T, Abreu AT, et al. Efficacy and Safety of Novel Probiotic Formulation in Adult Covid19 Outpatients: A Randomized, PlaceboControlled Clinical Trial. Gut Microbes. 2022;14(1):e2018899.
Dickson RP. The microbiome and critical illness. Lancet Respir Med. 2016;4(1):59-72.
Toscano M, De Grandi R, Stronati L, De Vecchi E, Drago L. Effect of Lactobacillus rhamnosus HN001 and Bifidobacterium longum BB536 on the healthy gut microbiota composition at phyla and species level: A preliminary study. World J Gastroenterol. 2017;23(15):2696-2704.
Bozkurt HS, Quigley EM. The probiotic Bifidobacterium in the management of Coronavirus: A theoretical basis. Int J Immunopathol Pharmacol. 2020;34:2058738420961304.
Din AU, Mazhar M, Waseem M, et al. SARSCoV-2 microbiome dysbiosis linked disorders and possible probiotics role. Biomed Pharmacother. 2021;133:110947.
Zhao S, Feng P, Meng W, Jin W, Li X, Li X. Modulated Gut Microbiota for Potential COVID-19 Prevention and Treatment. Front Med (Lausanne). 2022;9:811176.
Chen J, Vitetta L, Henson JD, Hall S. The intestinal microbiota and improving the efficacy of COVID-19 vaccinations. J Funct
How to Cite
Copyright (c) 2022 Asian Medical Journal and Alternative Medicine
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.